Background Total mesorectal excision (TME) combined with preoperative short-term radiotherapy (PRT) reduces local recurrence rates in rectal cancer treatment. However, treatment with radiotherapy increased morbidity and did not result in a longer survival. The aim of this analysis is to provide a comprehensive longitudinal overview of the health-related quality of life (HRQL) and symptoms experienced by rectal cancer patients in the Dutch randomized TME trial from baseline until 14 years after treatment.
Introduction
The introduction of total mesorectal excision (TME) resulted in a large decrease of local recurrence rates and an improved survival among patients treated for rectal cancer. 1 Additional treatment with preoperative radiotherapy (PRT) reduced the local recurrence rates even more. 2 However, preoperative radiotherapy did not prolong overall survival. 3 Due to this improved treatment, and the increasing incidence of rectal cancer, the number of long-term rectal cancer survivors is rising, underlining the importance of knowledge about late adverse effects and health-related quality of life (HRQL) after rectal cancer treatment. Most of the previous studies that assessed the HRQL and late side effects of rectal cancer survivors were crosssectional. In these studies more bowel and sexual dysfunction was found after radiotherapy, [4] [5] [6] although they concluded that sexual dysfunction was primarily caused by surgery. 7 In the few available longitudinal HRQL studies, the follow-up was at most until four years after treatment. [8] [9] [10] The main objective of this study was to present a longitudinal comprehensive overview of HRQL and symptoms of rectal cancer patients in the TME trial until 14 years after treatment. To provide this overview symptoms were categorized according to several patterns of symptom development over time, related either to the diagnosis of rectal cancer, surgery, radiotherapy or ageing.
Patients and methods

Study population
Between January 1996 and December 1999, 1530 Dutch patients with resectable rectal cancer were enrolled in the TME trial. Patients were randomly allocated to standardized TME surgery alone or to PRT followed by TME. The study design has been reported previously. 3, 6, 11, 12 Eligibility criteria consisted of a clinically resectable adenocarcinoma with an inferior tumour margin below the level of S1/ S2 and within 15 cm from the anal verge, without evidence of distant metastases. Patients assigned to PRT received a total dose of 25 Gy in five fractions delivered by a three or four-field technique over 5 to 7 days. The primary tumour and the mesentery containing the sacral, perirectal, and internal iliac nodes up to the S1/ S2 junction were included in the clinical target volume. The perineum was also included in this volume if an abdominoperineal resection (APR) was planned. Otherwise, the lower field border was 3 cm above the anal verge. 3, 6, 11, 12 50 51
Chapter 3
As the aim was to provide an overview of HRQL and symptoms until 14 years after treatment, only patients who were still alive and responded to the questionnaire at 14 years were included in this analysis. The study was approved by the ethics committee and informed consent was obtained from all patients.
Measurements
In the TME trial HRQL was measured at baseline, 3, 6, 12, 18 and 24 months (i.e. 0-2 years), 5 years and 14 years after treatment. 6, 12, 13 Different HRQL questionnaires were used (table 1) . Details of the questionnaires are reported previously. 6, 12, 13 For the majority of the questions from the Rotterdam Symptom Checklist 14 , the questionnaire used at 5 years 6 and the used EORTC questionnaires (core questionnaire: QLQ-C30 15 , colorectal modules: QLQ-CR29 16 and QLQ-38 17 , prostate module: QLQ-PR25 18 , cervix module: QLQ-CX24 19 ) four-point Likert-type scales were used. According to the guidelines of the EORTC Quality of life group, all item responses were linearly converted to 0 to 100 scales. Missing items were also handled following these guidelines 20 . A high score for functioning corresponds to a high level of functioning, whereas a high score for symptoms represents a high level of symptoms and thus a decreased HRQL.
Questions were only used for the comparisons if the exact wording and phrasing of the question corresponded between the different time points. Therefore, not all questions of the original questionnaires could be included. Furthermore, in the comparison between 5 and 14 years, 17 questions could not be converted to 0 to 100 scales, since the patients' answer options for these questions were continuous or dichotomous.
Statistics
Due to the use of different HRQL questionnaires (table 1) , no analysis of all time points could be performed, except for one question (pain during urination). Therefore, we conducted two separate analyses. One analysis compared the HRQL at 14 years to the HRQL at 5 years and one analysis compared the HRQL at 14 years to the HRQL reported at 0-2 years. The patient characteristics of the HRQL responders were compared using the independent t test for continuous variables and the x² test for the categorical variables. To compare the HRQL a linear mixed model was used with the patient as random effect and time, random assignment, and their interactions as fixed effects to obtain estimates for each fixed time point. The differences in HRQL were tested by Wald's tests. Analysis of all data was done with IBM SPSS statistics, version 20.0. To correct for multiple testing a two-sided P value of .01 was considered statistically significant. Differences between mean scores were small but clinically relevant, when differences were between 5 and 10 points on a scale of 100 points. A difference between 10 and 20 points was considered as moderate and a difference greater than 20 points was regarded as large. 21 After analysis, all items were categorized into four groups. Items were allocated to symptoms associated with the diagnosis of rectal cancer if the highest level of the symptom was reported at baseline (before treatment) of the study. If the highest increase of the symptom was reported at three months after randomisation, the symptom was allocated to surgery-related symptoms. Symptoms were allocated to radiotherapy-related symptoms if only irradiated patients reported a higher level of the symptom, and symptoms increasing towards 14 years after randomisation in both groups were allocated to the ageing-related symptoms. 
Results
Study population and compliance At 14 years after treatment 606 patients were alive in the TME trial. Nineteen patients refused further cooperation on HRQL analysis in 2003 and four patients were untraceable. Therefore, the HRQL questionnaire was sent to 583 patients. Of these patients, 478 responded to the HRQL questionnaire, resulting in a response rate of 82%. The EORTC QLQ-C30 was completed for all items in 82.2% of the responders, the EORTC QLQ-CR29 without the sexual items for 76.6%, and the questionnaire on bowel and urinary function for 59.9%. Allowing up to two missing items these rates were 95.1%, 92.4% and 84.6%, respectively. 13 Of these responders at 14 years, 368 patients had also replied to the questionnaire sent at 5 years after treatment and 422 patients also answered the HRQL questionnaire sent at baseline and at least one other questionnaire sent between 0-2 years after treatment. This resulted in 368 patients included in the analysis comparing HRQL at 14 and 5 years and in 422 included patients in the analysis comparing HRQL at 14 and 0-2 years (figure 1 and table 2). The compliance and response rates to the HRQL questionnaires at 0-2 and 5 years are previously reported. 6, 12 Patient characteristics for the responders at 14 years, the responders at 14 and 5 years and the responders at 14 and 0-2 years are listed in table 3. In all groups, irradiated patients were somewhat older than non-irradiated patients (median age at diagnosis 62 years in PRT+TME versus 60 years in TME, P=.04). Furthermore, in the group responders at 14 and 5 years more males were included in the PRT+TME group (65.2% males in PRT+TME versus 53.6% males in TME; P=.02). However, all other patient characteristics were equally balanced between the treatment arms and also no differences were found between the three groups of responders. In addition, age profiles at 14 years did not differ between responders and non-responders of the questionnaire. 13 
HRQL
For this overview symptoms were categorized as related to the diagnosis of rectal cancer, surgery, radiotherapy and ageing as defined in the methods section. However, some symptoms were influenced by more than one pattern. A summary of the influences of the different patterns on symptoms is listed in table 4. In table 5 and table 6 the mean scores and P-values are listed. Dutch patients TME trial (n=1530)
Allocated to preoperative short-term radiotherapy (PRT) and TME (n=761)
Allocated to total mesorectal excision (TME) (n=769) Abbreviations: HRQL, health-related quality of life; PRT, preoperative short-term radiotherapy; TME, total mesorectal excision; LAR, low anterior resection; APR, abdominoperineal resection. ◊ Difference between treatment arms of responders at 14 years ‡ Difference between treatment arms of responders at 14 and 5 years • Difference between treatment arms of responders at 14 and 0-2 years *For one irradiated patient and one non-irradiated patient, tumour location could not be determined. Abbreviations: PRT, preoperative short-term radiotherapy; TME, total mesorectal excision. For the symptom items, a higher score reflects a higher level of symptoms and decreased health-related quality of life. *Higher scores indicate better functioning and increased health-related quality of life. P randomisation compares the differences in scores between the two treatment arms after treatment. P time compares the differences in scores over time. P time*randomisation compares the differences over time between both treatment arms. Mean scores at baseline PRT+TME TME PRT+TME TME PRT+TME TME PRT+TME TME .91
Abbreviations: PRT, preoperative short-term radiotherapy; TME, total mesorectal excision.
For analysis all time points are used, however HRQL at 3,6, and 18 months are not included in this table.
For the symptom items, a higher score reflects a higher level of symptoms and decreased health-related quality of life. *Higher scores indicate better functioning and increased health-related quality of life.
P randomisation compares the differences in scores between the two treatment arms after treatment. 
Symptoms associated with the diagnosis of rectal cancer
The diagnosis of rectal cancer was associated with several increased symptoms at baseline (before treatment). These symptoms were difficulty sleeping, depressed mood, and tension. All these items showed a clinically relevant improvement within two years after baseline in both irradiated and non-irradiated patients. Furthermore, also abdominal aches, flatulence, diarrhoea, and difficulty concentrating decreased to a lesser extent after treatment. Flatulence even decreased until 14 years after treatment.
Surgery-related symptoms
After surgery all patients reported more incontinence for urine and more problems with emptying the bladder. The largest increase of urinary incontinence was reported in the first year after randomisation. After this first year a more gradually increase was found. Furthermore, all patients reported clinically relevant more anal pain, more faecal incontinence, and more sexual dysfunction after surgery and surgery was associated with more difficulties in social and family life and also with a higher level of tiredness (figure 2) and loss of hair. For these scores patients reported more symptoms and difficulties at 3 months (previously reported in detail 12 ).
Radiotherapy-related symptoms
Irradiated patients reported more bowel dysfunction, starting from 3 months after treatment. After 14 years, this bowel dysfunction was still reported by PRT+TME patients without stoma. Following surgery, all patients reported high levels of faecal incontinence. However, whereas faecal incontinence decreased until 14 years in non-irradiated patients, this symptom remained at the same (higher) level after two years in PRT+TME patients ( figure 3 ).
Ageing-related symptoms
As mentioned above, depressed mood, difficulty sleeping and tiredness were associated with the diagnosis of rectal cancer or surgical treatment. However, ageing also had a minor influence on these symptoms. This also counts for the general feeling during the last week, difficulties with family and social life, and symptoms such as dry mouth and incontinence for urine. Moreover, all patients reported an increase of pain in the hips, and difficulty walking towards 14 years after treatment. The difficulties with walking were also reflected by an increase in use of walking aids (PRT+TME versus TME at 5 years 6 versus 7 patients respectively, and at 14 years 45 versus 33 patients respectively; P time <.01).
Figure 2. Mean scores of the symptom tiredness
Abbreviations: PRT, preoperative short-term radiotherapy; TME, total mesorectal excision. A higher score reflects a higher level of the symptom and decreased health-related quality of life.
Figure 3. Mean scores of the symptom faecal incontinence
Abbreviations: PRT, preoperative short-term radiotherapy; TME, total mesorectal excision. A higher score reflects a higher level of the symptom and decreased health-related quality of life. Health-related quality of life (mean scores) Time (years) PRT+TME TME As described above increased levels of bowel dysfunction including faecal incontinence were seen after surgery but even more so after radiotherapy. In addition, patients reported use of more pads for faecal incontinence after 14 years (PRT+TME versus TME at 5 years 51.5% versus 30.5% respectively, and at 14 years 56.4% versus 37.1% respectively; P time <.01, P randomisation <.01). Finally, all patients were less bothered by noise of their stoma over time.
Discussion
This comprehensive longitudinal overview of HRQL in rectal cancer patients demonstrates that irradiated patients reported more bowel dysfunction than non-irradiated patients at all time points, even at 14 years after treatment. Moreover, general symptoms were not increased after irradiation. An increase in these general symptoms was seen at diagnoses of rectal cancer, after surgery, and ageing.
In this overview of HRQL, changes of scores over time were attributed to the presence of rectal cancer at baseline, TME surgery, short-course PRT or to the effect of aging. The analysis confirms that the largest changes in HRQL are related to treatment and are seen within the first two years after treatment. Symptoms related to the diagnosis of rectal cancer such as diarrhoea, flatulence but also tension and depressed mood show moderate improvement after treatment. The most relevant finding is the onset of bowel dysfunction, including faecal incontinence and anal mucus loss, with higher levels of dysfunction in irradiated patients. Importantly, faecal incontinence remains at a higher level in irradiated patients, while it decreases in patients who were not irradiated.
Several factors play a role in the persisting increased level of bowel dysfunction in irradiated patients. The gradual development of fibrosis together with microvasculature damage are well described underlying mechanisms of late radiation induced side effects and organ dysfunction. Physiological function is impaired at the level of the mucosa but also bowel motility, pelvic floor and sphincter muscle complex may be affected. Additional contributing factors such as bacterial overgrowth, bile acid malabsorption and lactose intolerance have been described. 22, 23 Research suggests that many patients have highly treatable bowel dysfunctions, if the cause of the dysfunction is correctly diagnosed. 24 Symptoms were categorized according to different patterns over time, with the purpose to facilitate the presentation of results in this comprehensive overview. The use of these specific categories was mainly triggered by the description of results by previous studies. These studies showed that symptoms caused by radiotherapy are still present after a longer follow-up time. 6, 25, 26 Furthermore, several population based studies found the effect of ageing in HRQL; patient functioning decreased and general symptoms increased. [27] [28] [29] [30] Underlining the importance of a randomized comparison between different treatment arms, since not all effects are due to the differences in treatment, but also due to ageing. In addition, if the highest increase of the symptom was reported at three months after randomisation, the symptom was allocated to surgery-related symptoms. This was based on a previous study, which reported that sexual dysfunction is primarily caused by surgery. The increase in sexual dysfunction was reported by patients at 3 months after surgery. 7 Although the use of these categories and patterns in this randomized setting are intuitive and straightforward in description, they cannot completely rule out possible confounders. Acute radiation toxicity could be a confounder for the surgery pattern, however very early results of the TME trial showed that acute toxicity after PRT usually resolved within a few weeks time. 31 Moreover, both radiotherapy and surgery could have a confounding effect in the ageing category. However, both the random allocation and the previously published comparison of the 14 year HRQL with an age and gender matched Dutch norm population, that revealed only small differences with regard to the general symptoms, make this unlikely.
Strengths of this detailed analysis of 14 years HRQL are the randomized trial design, with a surgery only group, the large number of included patients and the high response to the HRQL-questionnaires; 422 patients responded to the HRQL-questionnaire at baseline and at 14 years. Furthermore, as can been seen in the patients characteristics, both patients with a stoma and patients without a stoma participated in this long-term follow-up. By comparing all time points, from baseline until 14 years after treatment, we were able to provide a longitudinal overview of the development of HRQL, while most very long-term HRQL reports are cross-sectional.
The TME trial, that started accruing patients in 1996, was one of the earlier large randomized trials that prospectively measured quality of life. With the design of the trial prospective analysis using the validated Rotterdam symptom checklist during the first 2 years was anticipated. Due to the increasing experience and reported results using the EORTC quality of life questionnaires, these were integrated in the HRQL analysis at 14 years. Furthermore, since previous research concluded that more hip fractures and neurological problems were found after irradiation, the questions used at 5 years about difficulties with walking, and pain in de lower back and hips were included in the analysis at 14 years to especially evaluate these symptoms. Unfortunately due to the use of different questionnaires and due to differences in question wording and phrasing no sexuality questions for males and only two sexuality questions for females could be compared between 0-2 and 14 years. Therefore no conclusions could be drawn about general sexual functioning of females, neither about the sexual functioning of males over 14 years. However, previous HRQL analyses at 0-2 years and at 14 years irradiated patients reported more sexual dysfunction than surgery only patients. 12, 13 This finding is also supported by other studies. 8, 25 However, when the sexual function of both PRT+TME and TME patients is compared to the general population, TME patients also reported a decreased sexual function, 13, 25 which implies that surgery is, besides radiotherapy, also an important cause of sexual dysfunction in rectal cancer survivors. Several studies even concluded that surgery is the main cause for sexual dysfunction. 7, 8 Another source of possible bias is that only patients who responded to the HRQL questionnaire sent at 14 years are included in our analyses. However, comparing the HRQL mean scores with previous reported results of all responders at 0-2 years 12 revealed no differences, making biased results unlikely. Furthermore, irradiated patients were somewhat older than non-irradiated patients (median age at diagnosis 62 years in PRT+TME versus 60 years in TME, P=.04) which could cause a ageing bias in the scores of PRT+TME patients. However, given both the small difference (two years) in age between both groups and the magnitude of the effect of aging described in population-based studies, the additional effect of ageing is most likely negligible.
Only a few studies assessed long-term HRQL and adverse treatment effects in rectal cancer survivors; the TME trial 13 , the Swedish Rectal Cancer Trial 32 , the Stockholm trials 33 and a study on rectal cancer survivors in the Eindhoven Cancer Registry. 25 All these studies found approximately the same HRQL and adverse treatment effects as studies with a shorter follow-up time, which implies that besides natural ageing no large or moderate changes in HRQL of rectal cancer survivors after 5 years, or even after two years, are found. This finding shows that, except due to natural ageing, the HRQL of rectal cancer survivors remains stable during a longer follow-up time.
In conclusion, this longitudinal analysis shows that general symptoms in both groups are increased by at diagnosis of rectal cancer, after surgery and by ageing, but not by radiotherapy. However, irradiated patients reported more bowel dysfunction that persisted over time. These results can be used to counsel patients on what to expect with regard to their health related quality of life and symptoms during long-term follow-up and therefore also supports informed treatment decision-making. In addition, comprehensive strategies aimed to improve persisting late side effects of pelvic radiotherapy should be further explored.
